Alcoholic Liver Diseases Treatment Market worth USD 3,235.79 million by 2033

The Market Statsville Group (MSG) publishes the new report on the "Alcoholic Liver Diseases Treatment Market by Indication, by Treatment, by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region – Global Share and Forecast to 2033

According to the Market Statsville Group (MSG), the global Alcoholic Liver Diseases Treatment market size is expected to grow from USD 1,795.57 million in 2022 to USD 3,235.79 million by 2033, at a CAGR of 5.5% from 2023 to 2033.

Alcohol-related liver disease (ALD) is caused by consuming more alcohol than the liver can handle, causing damage to the organ. The liver, which is in responsible of several biological functions, processes what the body requires while eliminating what it does not required. The chemical process that occurs as the liver breaks down the alcohol generates a toxin that damages liver cells Several factors contribute to the increase in consumption, including rising disposable income and a growing urban population. In addition, poor eating habits and unhealthy lifestyle causes weight gain further leading to obesity. Obesity, followed by alcoholism, is the major cause of fatty liver disease in adults. On the other hand, The side effects associated with medications are expected to hamper the growth of the Alcoholic Liver Diseases Treatment market during the overall forecast period.

Global Alcoholic Liver Diseases Treatment Market Segmentation

The overall alcoholic liver diseases treatment market has been segmented into equipment, service, indication, and region.

• By Indication (Alcoholic Hepatitis, Alcoholic Steatohepatitis (Fatty Liver), Alcoholic Liver Fibrosis, Alcoholic Liver Cirrhosis)
• By Treatment (Pentoxifylline, Glucocorticosteroids, Betaine, Other Treatments)
• By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
• By Region (US, Canada, Mexico, UK, Germany, France, Italy, Spain, China, Japan, India, South Korea, Southeast Asia, Australia, Saudi Arabia, UAE, South Africa, Qatar, Nigeria, Israel, Brazil, Argentina, Peru)

Pentoxifylline segment is projected to dominate the market during the forecast period

Pentoxifylline segment is projected to dominate the market during the forthcoming period. As it promotes blood flow via blood vessels. It is used to treat leg discomfort caused by insufficient blood circulation. Pentoxifylline allows you to walk further before needing to rest due to leg cramps. This product is available in the dosage forms such as Tablet, Extended Release. Along with its effects, a medicine may cause some unwanted effects such as Chest pain, irregular heartbeat, Drowsiness, Flushing, Faintness, unusual excitement, and others. This can increase the amount of oxygen that can be delivered by the blood when the muscles need more (such as during exercise) thereby increasing walking distance and duration.

Don't miss out on business opportunities in Alcoholic Liver Diseases Treatment Market. Speak to our research analyst and gain crucial market insights that will benefit your business grow.

The Asia Pacific to account for the highest CAGR during the forecast period

China holds majority share in Asia Pacific Alcoholic Liver Disease Treatment market in 2022 due to the consumption of bad and cheap alcohol and in this region, alcohol is cheaper than the other region. The total alcohol consumption per capita remained at the level of 6.4 L (equivalent to 13.9 g of pure alcohol per day) globally over the period 2010–2016, but that was increased from 7.1 to 7.2 L in China. Consequently, the number of alcohol-attributable deaths also increased from 484,000 to 670,000 over the past decade (from 2007 to 2017). The burden caused by alcohol use has become the third highest behavioral risk factor after inappropriate diet and smoking in China. These consumption rates of alcohol form public will boost the market growth for the upcoming period.

This research report includes a study on the development and marketing strategies, along with a study on the product portfolios and winning strategies of the leading companies operating in the alcoholic liver diseases treatment market. It also consists of the profiles of leading companies such as F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Pfizer Inc., Novartis AG, Akorn Operating Company LLC, Johnson & Johnson Services, Inc., Wellona Pharma, Teva Pharmaceuticals USA, Inc., Tianjin Jinjin Pharmaceutical Co. Ltd and AdvaCare Pharma. The key players' growing research and development activities for launching innovative healthcare devices with advanced features and strategic unions are expected to drive market growth.

About Market Statsville Group

Market Statsville Group (MSG) is a business research and consulting platform of Statsville Consulting Private Limited, based in Oklahoma, USA. MSG is the leading market research and strategy builder with the depth and breadth of solutions that perfectly suit your every need. MSG provides solutions in a wide range of industry verticals in market sizing, analysis, and intelligent business insights. MSG has experienced research analysts who are proficient at digging deep and providing various customizable data that help you make decisions with clarity, confidence, and impact. Furthermore, Market Statsville Group already benefited more than 1,000 companies each year for their revenue planning. It helped them take their disruptions/innovations early to the market by providing them research ahead of the curve.

MSG has an entire repository of research reports on more than 1,000 niche industries, 3,000 high-growth potentials markets, 5,000 data sets, and more than 12,000 company profiles.

Contact Us:

Market Statsville Group

800 Third Avenue Suite A #1519

New York, US 10022

USA: +1 646-663-5829 | +91 702 496 8807

Email: sales@marketstatsville.com

Web: www.marketstatsville.com